AAV Micro-Dystrophin Delivery for Muscle Membrane Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Muscular dystrophies, such as Duchenne Muscular Dystrophy (DMD), result in muscle weakness and fibrosis due to the loss of dystrophin, leading to uncontrolled muscle degeneration and fibrotic scarring, necessitating treatments that increase muscle strength and protect against injury.
Innovation Solution
Gene therapy vectors, particularly AAV vectors expressing micro-dystrophin, are administered to skeletal and cardiac muscles to stabilize muscle membranes, increase muscle strength, and reduce fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If dystrophin is lost due to genetic mutation, then muscle membrane stability deteriorates, but muscle strength and function are preserved initially
Solution Approach 1:
The patent applies segmentation by delivering a miniaturized version of the dystrophin gene (micro-dystrophin) that codes for a truncated, functional dystrophin protein. This segmented approach allows the gene to be packaged in a manageable size for viral vector delivery while still producing a functional protein that stabilizes muscle membranes and prevents fibrosis, resolving the contradiction between membrane stability and muscle strength preservation.
Solution Approach 2:
The patent changes the parameter of dystrophin expression by introducing a miniaturized gene sequence that produces a truncated dystrophin protein with reduced molecular weight but retained functional activity. This parameter change enables the protein to stabilize muscle membranes and prevent fibrosis without requiring the full-length dystrophin gene, thus addressing both membrane stability and muscle strength requirements.
2Strength
If muscle fibers undergo uncontrolled degeneration and regeneration, then muscle strength decreases, but fibrotic scarring increases
Solution Approach 1:
The patent applies preliminary action by introducing micro-dystrophin expression before significant fibrotic scarring occurs. The miniaturized dystrophin gene is delivered via AAV vectors to establish functional dystrophin protein expression in muscle fibers prior to the onset of uncontrolled degeneration and fibrosis, thereby preventing the harmful effects rather than treating them after they manifest.
Solution Approach 2:
The patent converts the harmful effect of dystrophin loss into a benefit by introducing a miniaturized dystrophin gene that specifically targets and stabilizes muscle membranes. This truncated dystrophin protein prevents the uncontrolled degeneration and fibrosis that would otherwise occur, transforming the pathological process into a protective mechanism that preserves muscle strength and prevents fibrotic scarring.
3Stability of the object's composition
If full-length dystrophin gene is delivered, then muscle membrane stability improves, but vector delivery efficiency decreases
Solution Approach 1:
The patent applies segmentation by dividing the full-length dystrophin gene into a miniaturized version (micro-dystrophin) that is sufficiently small to be efficiently packaged and delivered by AAV vectors. This segmented approach maintains the essential functional domains of dystrophin required for membrane stability while reducing the gene size to improve vector delivery efficiency and transduction rates.
Solution Approach 2:
The patent changes the parameter of gene size by using a miniaturized dystrophin gene sequence that encodes a truncated protein. This parameter change allows the gene to fit within the capacity limits of AAV vectors, significantly improving delivery efficiency and transduction efficiency while still producing a functional dystrophin protein that stabilizes muscle membranes.
Data Source
AI summary
The invention provides gene therapy vectors, such as adeno-associated virus (AAV) vectors, expressing a miniaturized human micro-dystrophin gene and method of using these vectors to express micro-dystrophin in skeletal muscle s including diaphragm and cardiac muscle and to protect muscle fibers from injury, increase muscle strength and reduce and/or prevent fibrosis in subjects suffering from muscular dystrophy.